|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hotta K, Matsuo K, Ueoka H, Kiura K,
Tabata M and Tanimoto M: Meta-analysis of randomized clinical
trials comparing cisplatin to carboplatin in patients with advanced
non-small-cell lung cancer. J Clin Oncol. 22:3852–3859. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Belli C, Fennell D, Giovannini M, Gaudino
G and Mutti L: Malignant pleural mesothelioma: Current treatments
and emerging drugs. Expert Opin Emerg Drugs. 14:423–437. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vogelzang NJ, Rusthoven JJ, Symanowski J,
et al: Phase III study of pemetrexed in combination with cisplatin
versus cisplatin alone in patients with malignant pleural
mesothelioma. J Clin Oncol. 21:2636–2644. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Scagliotti GV, Parikh P, von Pawel J, et
al: Phase III study comparing cisplatin plus gemcitabine with
cisplatin plus pemetrexed in chemotherapy-naive patients with
advanced-stage non-small-cell lung cancer. J Clin Oncol.
26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hong J, Kyung SY, Lee SP, et al:
Pemetrexed versus gefitinib versus erlotinib in previously treated
patients with non-small cell lung cancer. Korean J Intern Med.
25:294–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chattopadhyay S, Moran RG and Goldman ID:
Pemetrexed: Biochemical and cellular pharmacology, mechanisms, and
clinical applications. Mol Cancer Ther. 6:404–417. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Buqué A, Muhialdin JS, Muñoz A, Calvo B,
Carrera S, Aresti U, Sancho A, Rubio I and López-Vivanco G:
Molecular mechanism implicated in pemetrexed-induced apoptosis in
human melanoma cells. Mol Cancer. 11:252012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Smith BC, Hallows WC and Denu JM:
Mechanisms and molecular probes of sirtuins. Chem Biol.
15:1002–1013. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huffman DM, Grizzle WE, Bamman MM, Kim JS,
Eltoum IA, Elgavish A and Nagy TR: SIRT1 is significantly elevated
in mouse and human prostate cancer. Cancer Res. 67:6612–6618. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim JE, Chen J and Lou Z: DBC1 is a
negative regulator of SIRT1. Nature. 451:583–586. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen WY, Wang DH, Yen RC, Luo J, Gu W and
Baylin SB: Tumor suppressor HIC1 directly regulates SIRT1 to
modulate p53-dependent DNA-damage responses. Cell. 123:437–448.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Campisi J: Suppressing cancer: The
importance of being senescent. Science. 309:886–887. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ota H, Tokunaga E, Chang K, Hikasa M,
Iijima K, Eto M, Kozaki K, Akishita M, Ouchi Y and Kaneki M: Sirt1
inhibitor, Sirtinol, induces senescence-like growth arrest with
attenuated Ras-MAPK signaling in human cancer cells. Oncogene.
25:176–185. 2006.
|
|
15
|
Wolf CM and Eastman A: The temporal
relationship between protein phosphatase, mitochondrial cytochrome
c release, and caspase activation in apoptosis. Exp Cell Res.
247:505–513. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Elbashir SM, Harborth J, Lendeckel W,
Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs
mediate RNA interference in cultured mammalian cells. Nature.
411:494–498. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ciuleanu T, Brodowicz T, Zielinski C, et
al: Maintenance pemetrexed plus best supportive care versus placebo
plus best supportive care for non-small-cell lung cancer: A
randomised, double-blind, phase 3 study. Lancet. 374:1432–1440.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ramirez JM, Ocio EM, San Miguel JF and
Pandiella A: Pemetrexed acts as an antimyeloma agent by provoking
cell cycle blockade and apoptosis. Leukemia. 21:797–804.
2007.PubMed/NCBI
|
|
19
|
Tonkinson JL, Worzalla JF, Teng CH and
Mendelsohn LG: Cell cycle modulation by a multitargeted antifolate,
LY231514, increases the cytotoxicity and antitumor activity of
gemcitabine in HT29 colon carcinoma. Cancer Res. 59:3671–3676.
1999.PubMed/NCBI
|
|
20
|
Chen KC, Yang TY, Wu CC, Cheng CC, Hsu SL,
Hung HW, Chen JW and Chang GC: Pemetrexed induces S-phase arrest
and apoptosis via a deregulated activation of Akt signaling
pathway. PLoS One. 9:e978882014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang TY, Chang GC, Chen KC, Hung HW, Hsu
KH, Wu CH, Sheu GT and Hsu SL: Pemetrexed induces both intrinsic
and extrinsic apoptosis through ataxia telangiectasia
mutated/p53-dependent and -independent signaling pathways. Mol
Carcinog. 52:183–194. 2013. View
Article : Google Scholar
|
|
22
|
Copeland WC, Wachsman JT, Johnson FM and
Penta JS: Mitochondrial DNA alterations in cancer. Cancer Invest.
20:557–569. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim HR, Yang SH and Jeong ET: Combination
treatment with arsenic trioxide and sulindac induces apoptosis of
NCI-H157 human lung carcinoma cells via ROS generation with
mitochondrial dysfunction. Tuberc Respir Dis. 59:30–38. 2005.
|
|
24
|
Green DR and Reed JC: Mitochondria and
apoptosis. Science. 281:1309–1312. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li LY, Luo X and Wang X: Endonuclease G is
an apoptotic DNase when released from mitochondria. Nature.
412:95–99. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tournier C, Hess P, Yang DD, Xu J, Turner
TK, Nimnual A, Bar-Sagi D, Jones SN, Flavell RA and Davis RJ:
Requirement of JNK for stress-induced activation of the cytochrome
c-mediated death pathway. Science. 288:870–874. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Burdon RH: Control of cell proliferation
by reactive oxygen species. Biochem Soc Trans. 24:1028–1032.
1996.PubMed/NCBI
|
|
28
|
Balaban RS, Nemoto S and Finkel T:
Mitochondria, oxidants, and aging. Cell. 120:483–495. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ozben T: Oxidative stress and apoptosis:
Impact on cancer therapy. J Pharm Sci. 96:2181–2196. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tan S, Sagara Y, Liu Y, Maher P and
Schubert D: The regulation of reactive oxygen species production
during programmed cell death. J Cell Biol. 141:1423–1432. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim EJ, Kho JH, Kang MR and Um SJ: Active
regulator of SIRT1 cooperates with SIRT1 and facilitates
suppression of p53 activity. Mol Cell. 28:277–290. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Brunet A, Sweeney LB, Sturgill JF, et al:
Stress-dependent regulation of FOXO transcription factors by the
SIRT1 deacetylase. Science. 303:2011–2015. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Westerheide SD, Anckar J, Stevens SM Jr,
Sistonen L and Morimoto RI: Stress-inducible regulation of heat
shock factor 1 by the deacetylase SIRT1. Science. 323:1063–1066.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Raynes R, Brunquell J and Westerheide SD:
Stress inducibility of SIRT1 and its role in cytoprotection and
cancer. Genes Cancer. 4:172–182. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kawai Y, Garduño L, Theodore M, Yang J and
Arinze IJ: Acetylation-deacetylation of the transcription factor
Nrf2 (nuclear factor erythroid 2-related factor 2) regulates its
transcriptional activity and nucleocytoplasmic localization. J Biol
Chem. 286:7629–7640. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yeung F, Hoberg JE, Ramsey CS, Keller MD,
Jones DR, Frye RA and Mayo MW: Modulation of NF-kappaB-dependent
transcription and cell survival by the SIRT1 deacetylase. EMBO J.
23:2369–2380. 2004. View Article : Google Scholar : PubMed/NCBI
|
